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Abstract. To assess the spectrum of illness from toxigenicVibrio choleraeO1 and risk factors for severe cholera in Haiti,
we conducted a cross-sectional survey in a rural commune with more than 21,000 residents. During March 22–April 6,
2011, we interviewed 2,622 residents ³ 2 years of age and tested serum specimens from 2,527 (96%) participants for
vibriocidal and antibodies against cholera toxin; 18% of participants reported a cholera diagnosis, 39% had vibriocidal
titers ³ 320, and 64% had vibriocidal titers ³ 80, suggesting widespread infection. Among seropositive participants
(vibriocidal titers ³ 320), 74.5% reported no diarrhea and 9.0% had severe cholera (reported receiving intravenous fluids
and overnight hospitalization). This high burden of severe cholera is likely explained by the lack of pre-existing immunity
in this population, although the virulence of the atypical El Tor strain causing the epidemic and other factors might also
play a role.
INTRODUCTION
Epidemic cholera was introduced to Haiti for the first time
in October 2010,1,2 causing one of the worst cholera outbreaks
in recorded history with 651,339 illnesses and 8,053 deaths as
of March 24, 2013.3 Because infection with toxigenic Vibrio
cholerae O1 results in a wide spectrum of illness,4 estimates
of disease severity are important for projecting resource
needs (e.g., intravenous [IV] fluids and medical staffing) and
planning response efforts. Most infections with toxigenic
V. cholerae are asymptomatic; a smaller proportion of infected
persons develop mild or moderate diarrhea, and only a small
percentage of those exposed develop severe cholera.4 Previous
studies in Bangladesh, a country in which cholera has been
endemic for centuries, have suggested that an estimated 2% of
persons infected with typical seventh pandemic V. cholerae O1
biotype El Tor develop severe cholera compared with 11% of
those infected with the classical biotype.5–7 The relevance of
these estimates in cholera-naive countries such as Haiti is
unknown. In addition, altered or atypical strains with charac-
teristics of both biotypes have emerged in South Asia,8 Africa,9
and now in Haiti.9 The V. cholerae strain introduced to Haiti is
a fully virulent serogroup O1, serotype Ogawa, with an inte-
grated El Tor type phage (CTXF)El Tor that expresses the
classical ctxB-1 allele.9 Limited evidence suggests that certain
atypical El Tor strains might be more virulent than previous El
Tor strains.10,11
Host factors play a role in determining cholera severity.12
Persons with ABO blood group O have been shown to have
higher rates of severe cholera compared with persons with
other ABO blood groups.13–15 Prevalence of blood group O
ranges widely across populations,16 which likely influences the
resulting clinical spectrum of illness from V. cholerae infec-
tion. We found no published reports of blood group distribu-
tion in Haiti. Other risk factors related to development of
symptomatic cholera are low gastric acidity,17,18 retinol defi-
ciency,12 and, potentially, iron deficiency.19
Antibodies measured by the vibriocidal test, which is an
antibody-dependent, complement-mediated lytic assay, are
considered to be markers of recent exposure to V. cholerae.
Vibriocidal assays are widely used as evidence of infection
in serosurveys,5,6 case–control studies,14 and for surveillance
in the United States.20 When used in populations, results cor-
relate well with protection from V. cholerae infection and
symptomatic disease.21 In volunteer studies, vibriocidal titers
peak soon after exposure and usually return to baseline within
a year in the absence of re-infection.22 Although vibriocidal
antibodies are cross-reactive between the two V. cholerae
serotypes, Ogawa and Inaba, responses are typically highest
to the homologous strain. Serum IgG to cholera toxin (CT)
are not associated with immunity, but are markers of recent
or previous toxigenic V. cholerae infection, and typically
remain elevated for over a year.23,24 However, cross-reactivity
between CT and the heat-labile toxin produced by some
enterotoxigenic Escherichia coli can produce false-positive
results in anti-CT testing, which limits its usefulness in deter-
mining recent V. cholerae infections. In cholera-endemic areas,
serum IgA anti-CT has a similar decay pattern to vibriocidal
antibodies and may be associated with immunity.12,24
To characterize the spectrum of illness resulting from epi-
demicV. cholerae infection in aHaitian population and examine
risk factors for severe disease,weconducted a seroepidemiologic
survey in Grande Saline Commune, Artibonite Department,
Haiti. This commune reported a high cholera attack rate (18%)
from October 2010 through March 2011 (Ministère de la Santé
Publique et de la Population [MSPP] Surveillance, unpublished
data), suggestive of widespread V. cholerae exposure. Grande
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Saline, which is located along the terminal portion of the
Artibonite River, was one of the first communes affected by the
outbreak25 and is highly reliant on river water for agricultural
and domestic use. The commune’s estimated 21,131 residents26
live primarily in 13 villages situated along a single road that
follows the river. In the five months between the start of the
outbreak and the seroepidemiologic study, the commune was
served by a single cholera treatment center. We interviewed
participants regarding cholera symptoms and treatment and
collected serum for vibriocidal and anti-CT testing as markers
ofV. cholerae exposure.
MATERIALS AND METHODS
Study design and participant selection. During March 22–
April 6, 2011, we conducted a cross-sectional seroepide-
miologic survey in Grande Saline Commune. All consenting
residents ³ 2 years old from selected households were eligible
for enrollment. After accounting for non-participation and
design effect, our target sample was 600 households, based on
assumptions of four consenting persons per household (for
2,400 participants) and a 75% V. cholerae infection rate. The
true infection rate was unknown; 75% was chosen for these
calculations because the high reported cholera attack rate in
the commune suggested widespread exposure. This sample size
would estimate the proportion of infected persons who develop
severe disease to within 4%, assuming 5% of seropositive par-
ticipants developed severe disease (given previous estimates
of 2–11%).5–7 We used a type I error rate of 5% and power of
80% for sample size calculations.
The sampling frame included all households within the com-
mune located in the commune’s 13 villages (Figure 1). Local
authorities reported that nearly all commune residents resided
within these villages, which are all located along the com-
mune’s main road. We selected households within each village
in proportion to population estimates from local authorities
because current census data were not available at the munici-
pal level. Local community health workers identified sub-
sections of each village. Study teams enrolled households
within all subsections by starting at local landmarks within each
section and moving sequentially from household to household.
We used satellite maps of villages to minimize exclusion
of household groups.
Data and serum collection. Study teams interviewed partic-
ipants by using a Visual CE (SYWARE, Cambridge, MA)
electronic questionnaire on a personal digital assistant. The
survey included questions about demographic and household
characteristics, reported cholera diagnosis by a health care
provider, diarrheal symptoms and treatment, antacid use,
and deaths caused by cholera within the household since the
start of the outbreak in October 2010. Within each household,
we asked the first participant encountered (or parent or
guardian for children less than 12 years old) about household
characteristics (e.g., number of persons in household and pri-
mary water source) and individual characteristics, and asked
subsequent participants only about individual characteristics.
We used a household identification number to link records
within a household. All information was self-reported (or for
children < 12 years old, reported by a parent or guardian),
including clinical information; detailed clinical records were
not available. We collected a single blood specimen from
consenting participants as described below.
Human subjects protection. Institutional Review Boards
from the Haitian National Ethics Committee (Protocol
#2011-FWD-CHOLERA-01) and the U.S. Centers for Dis-
ease Control and Prevention (CDC Protocol #6038) granted
approval for this study, including for testing of control serum
specimens. Haitian interviewers provided participants with
oral and written explanations of the study. Participants
marked checkboxes to indicate informed consent (adults ³ 18
years old), parent or guardian permission (children < 18 years
old), and child assent (children 7–17 years old). No personal
identifiers were collected.
Serum collection and processing. Blood specimens were
collected in volumes consistent with participants’ age and
weight (maximum = 10 mL) in Vacutainer (Tiger Red/Black
Top; Becton-Dickinson Laboratories, Franklin Lakes, NJ)
serum separator tubes and transported on cold packs to the
local health center in Grand Saline Commune. At a tempo-
rary serum processing laboratory in the health center, serum
was separated after centrifuging the blood specimens, labeled,
and stored on cold packs until the end of each workday.
Serum specimens were transferred to a refrigerator at the
Hôpital Albert Schweitzer, Haiti, and were transported twice
a week on cold packs to the National Public Health Labora-
tory in Port-au-Prince. They were then held refrigerated until
shipment to CDC (Atlanta, GA). At CDC, specimens were
inventoried and accessioned, and each specimen was divided
into 0.5-mL aliquots and frozen at −80°C. Fifty unlinked
control serum specimens collected in Haiti before the cholera
outbreak were included to determine pre-2010 antibody levels
in this population.
Strains. Two V. cholerae strains from Haiti, 2010EL-1786
(serotype Ogawa) and 2012EL-1407 (serotype Inaba), were
used as target antigens in the vibriocidal assays. The complete
genome sequence of 2010EL-1786 has been published.27 The
Inaba strain 2012EL-1407 emerged in Haiti in March of 2012.28
Figure 1. Grande Saline Commune, Haiti, with locations of
13 cholera serosurvey study villages.
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Preliminary bacterial growth curves aided in standardizing
the inoculum, time of incubation, and growth medium neces-
sary to achieve a target inoculum of 3.0 +107 colony-forming
units/mL of live bacteria in the early log phase of growth. The
Ogawa isolate was grown to early log phase in BactoTM
Heart Infusion Broth (Becton Dickinson and Company,
Sparks, MD), divided into aliquots, and frozen at −80°C. From
pilot study results, we concluded that 3 hours of incubation at
37°C of a standard inoculum from the frozen stock yielded
3.0 +107 colony-forming units/mL. Thereafter, on each assay
occasion we determined the final concentration of live bacte-
ria. If the counts did not fall within 1 SD of the average
of all accepted runs, we rejected the previous day’s assay.
We repeated this process for the Inaba serotype.
Complement. Three lots of commercial guinea pig com-
plement (Innovative Research, Novi, MI) were tested in
pilot studies. The best performing lot was selected, and all
serotype-specific assays were run using the same lot. Pilot
studies of complement activity aided in standardizing the
assay to assure addition of excess complement. Controls were
run to ensure that commercial complement did not contain
naturally occurring vibriocidal activity.
Controls. Known positive serum specimens obtained from
patients with confirmed cholera infections and known nega-
tive specimens were run on each test occurrence for each
assay. Controls were unlinked from any patient identifiers.
Vibriocidal assays. Both serotype-specific assays were vali-
dated with known positive and negative serum specimens and
a positive cutoff was established by receiver operating charac-
teristic analysis. The assays in a 96-well microtiter format
were set up accordingly: two-fold dilutions of heat-inactivated
control and test serum samplers were titrated by using a
BioMekNXPLaboratoryAutomationWorkstation (Beckman
Coulter, Brea, CA). After an initial 1:10 dilution of each
serum, 11 two-fold dilutions were made to a final concentra-
tion of 1:40,560. Every serum specimen was run in duplicate.
All specimens were tested with serotype Ogawa and repeated
with serotype Inaba.
For each assay, the appropriate V. cholerae strain was cul-
tured at 37°C to early log phase and washed twice. Cultures
and complement were mixed, added to each serum dilution,
incubated for 1 hour at 37°C, then overlayed with warmed
BactoTMHeart Infusion Broth. After 2.5 hours at 37°C, wells
were read visually for turbidity indicating growth of bacteria.
The titer was expressed as the reciprocal of the highest dilu-
tion of serum with > 50% reduction in turbidity. If positive
controls results did not fall within one dilution ± 1:640, or if
the negative control was positive at any dilution, the assay was
rejected and re-tested. In addition, if plate counts did not fall
within 1 SD of the average of previously validated specimens,
the corresponding assay was rejected and re-tested.
Anti-CT IgG and IgA. We tested serum specimens in an
indirect enzyme-linked immunosorbent assay (ELISA) format
using Immulon 2HB (Thermo Scientific, Rochester, NY) micro-
titer plates coated with commercially available CT (Sigma,
St. Louis, MO). Individual serum specimens were diluted 1:50
in phosphate-buffered saline with 1% bovine serum albumin
and diluted two-fold to 1:1600, followed by the addition of
mouse anti-human IgG monoclonal antibody HP604329 or com-
mercial goat anti-human IgA (Invitrogen, Frederick, MD) con-
jugated to alkaline phosphatase. After incubation for 1 hour
at 37°C, we added disodium p-nitrophenyl phosphate (Sigma),
stopped the reaction with 3M NaOH, and read optical densities
(ODs) at 405 nm with a Spectramax Plus 384 device (Molecular
Devices, Sunnydale, CA).
We optimized antigen, serum, and conjugates by checker-
board titrations before testing and validated ELISA results by
using positive and negative serum from patients with and
without cholera, respectively. Statistical thresholds were cal-
culated by using receiver operating characteristic analysis for
each assay and antibody class.
Blood group. Since red cells were not available, we deter-
mined ABO blood group for a subset of participants by using
the reverse-typing test tube method with A1 and BReferencells
(Immucor, Norcross, GA) as specified by the manufacturer.
Anti-A and Anti-B murine monoclonal antibodies (Immucor)
were tested as controls. A limitation of this approach is that it
does not directly detect ABO blood groups but rather depends
on the presence of anti-A and anti-B antibodies in serum.
Data analysis. Survey data were downloaded from personal
digital assistants to a Microsoft (Redmond, WA) Access 2003
Table 1
Demographic characteristics and diarrhea histories of 2,622 cholera























Yes 11 < 1
Refused/do not know 108 4
Missing 3 < 1
Reported pregnant, among females






Refused/do not know 3 < 1
Missing 3 < 1
Watery diarrhea since October 2010†
No 1,998 79
Yes 541 21
Refused/do not know 3 < 1
Missing 1 < 1
Cholera diagnosis since October 2010†
No 2,074 82
Yes 466 18
Missing 3 < 1
*HIV = human immunodeficiency virus.
†Excludes 79 participants who reported cholera but not watery diarrhea.
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database and analyzed by using SAS version 9.3 (SAS Insti-
tute, Cary, NC).
Seropositivity was determined by measuring vibriocidal
antibody responses to Ogawa and Inaba serotypes from
isolates obtained from Haiti. Secondary analyses examined
anti-CT IgA and anti-CT IgG results. We defined clinical
severity of disease by level of treatment required, similar to
definitions from previous bacteriological surveys.5,6 All clini-
cal data were self-reported. Participants who reported a chol-
era diagnosis but not watery diarrhea (i.e., logically
inconsistent responses) were excluded from analyses describ-
ing cholera and disease severity.
Severe disease was defined as diarrhea with overnight hos-
pitalization at a health facility and receipt of IV fluids, mod-
erate disease as diarrhea and a visit to a health facility but not
meeting criteria for severe disease, and mild disease as diar-
rhea without a health facility visit.
We calculated basic frequencies, as well as odds ratios
(ORs) and 95% confidence intervals (CIs) by using simple
logistic regression adjusted for household design effect. We
used proportional-odds cumulative logistic regression models
to assess influence of potential risk factors on disease severity
(classified on a four-level ordinal scale: severe, moderate, mild,
or asymptomatic), adjusting for age quartile, and antacid use.
Predictors were blood group and socioeconomic characteristics
(literacy, speaking French, and household possession of a cell
phone, radio, or electricity). For each model, we calculated the
score test to assess whether the proportional odds assumption
was contradicted.
RESULTS
Enrollment. During the study period, we enrolled 2,622
Grande Saline residents ³ 2 years old from 1,240 households.
There were an average of 4.4 (SD = 2.5) eligible persons
per household of whom we enrolled a mean of 2.1 partici-
pants (range = 1–10). Enrollment targets were met in each of
the commune’s 13 villages. We collected serum from 2,527
(96%) participants.
Demographic and socioeconomic characteristics. The
median age of participants was 23 years (range = 2–90 years),
and 59% were female (Table 1). The median age for males
(18 years) was less than the median age for females (26 years);
among adults ³ 18 years old, 1,013 (65%) were women, and
544 (35%) were men. Among all participants, 1,394 (53%)
were literate, 300 (11%) spoke French, and 257 (10%) had
attended at least some secondary school. Among 1,557 adults
³ 18 years old, 729 (47%) were literate, 220 (14%) spoke
French, and 219 (14%) attended at least some secondary
school. The most common occupations among adults were
rice farming (565, 36%), farming other crops (343, 22%), and
vending or trading (307, 20%).
Household characteristics. Among the 1,240 households
in the study, 603 (49%) owned a cellular phone, 434 (35%)
owned a radio, and 52 (4%) had electricity (including from
generators). Regarding primary drinking water source, 472
(38%) households bought water from vendors, 398 (32%)
households used a canal or the Artibonite River, 180 (15%)
used a public or private tap, and the remaining 190 (15%)
used other sources, including wells. Of 962 (78%) households
that reported having treated their drinking water since the
outbreak began, 953 (99%) used at least one of three treat-
ment methods: 513 (53%) used chlorine tablets, 246 (26%)
used filters, 91 (9%) used chlorine solution, and 112 (12%)
used a combination of these methods. No additional informa-
tion was collected on alternate sources of drinking water or
the regularity of drinking water treatment.
Health characteristics. Eleven (< 1%) participants reported
having been diagnosed with HIV infection, 77 (7%) females
10–55 years old reported being pregnant, and 418 (16%) par-
ticipants reported taking antacids in the previous six months.
Blood group testing. We tested a subset of 866 participants
for ABO blood groups by reverse typing; 386 (45%) had
blood group O, 242 (28%) had group A, 194 (22%) had group
B, and 44 (5%) had group AB.
Diarrhea and cholera. Among all participants, 541 (21%)
reported an episode of watery diarrhea since the start of the
cholera outbreak in October 2010, including 466 (18%) who
Table 2
Clinical characteristics of cholera serosurvey participants reporting watery diarrhea, Grande Saline, Haiti, March 22–April 6, 2011*
Characteristic
Cholera diagnosis (n = 466) Watery diarrhea only (n = 75) Any watery diarrhea (n = 541)
No. or median % or IQR No. or median % or IQR No. or median % or IQR
Rice water stool 429 92 19 25 448 83
Leg cramps 361 77 23 31 384 71
Vomited more than once 225 48 10 13 235 43
Bloody stool 50 11 7 9 57 11
Maximum no. stools in 24 hours 7 4–10 3 3–4 6 3–10
Used ORS at home 405 87 45 60 450 83
Took antibiotic 315 68 47 63 362 67
Went to HF 366 79 21 28 387 72
Treatment at HF (among participants who visited HF) (n = 366) (n = 21) (n = 387)
Received ORS at HF 329 90 11 52 340 88
Received IV fluids at HF 213 58 7 33 220 57
Hospitalized overnight 191 52 5 24 196 51
IV fluids and hospitalization 157 43 0 0 157 41
Disease severity (n = 466) (n = 75) (n = 541)
Mild† 99 21 54 72 153 2
Moderate‡ 209 45 21 28 230 43
Severe§ 157 34 0 0 157 29
*IQR = interquartile range; ORS = oral rehydration salts; HF = health facility; IV = intravenous.
†Defined as watery diarrhea without a visit to an HF.
‡Defined as watery diarrhea with an HF visit, but not meeting criteria for severe disease.
§Defined as watery diarrhea with receipt of IV fluids and overnight hospitalization.
CHOLERA SEROEPIDEMIOLOGIC SURVEY IN HAITI 657
reported a cholera diagnosis from a health care worker (Table 1).
Seventy-nine (3%) participants reported a cholera diagnosis but
no watery diarrhea and were excluded from cholera and disease
severity analyses. Among the 541 participants reporting watery
diarrhea, 83% reported feces that resembled water used to cook
rice (rice water stool), 71% reported painful leg cramps, 43%
reported vomiting more than once, and 11% reported bloody
stool (Table 2). Participants with watery diarrhea who reported
a cholera diagnosis were more than twice as likely as partici-
pants with watery diarrhea without a cholera diagnosis to report
each of these symptoms except for bloody stool, for which the
proportions were similar (11% versus 9%, respectively). Partic-
ipants with a cholera diagnosis reported a median of seven
stools on the worst day of illness compared with three for those
not reporting a cholera diagnosis. Most participants reported a
date of diarrhea onset during October 15–November 31, 2010
(Figure 2A). This distribution of illness over time was similar to
the distribution of cholera cases reported to Haiti’s national
cholera surveillance system by local health care providers in
Grande Saline (Figure 2B).
Regarding treatment, 87% of participants who reported a
cholera diagnosis had used oral rehydration salts at home,
68% took an antibiotic during the diarrheal episode, and
79% (366 participants) sought treatment at a health facility.
Among the 366 participants who reported a cholera diagnosis
and treatment at a health facility, 90% reported receiving oral
rehydration salts during their stay, 58% reported receiving IV
fluids, and 52% reported being hospitalized overnight; 157
(43%) reported both IV fluids and overnight hospitalization.
We classified disease severity among participants with watery
diarrhea based on level of treatment received (Table 2).
Of participants reporting a cholera diagnosis, 21% had mild
disease, 45% had moderate disease, and 34% had severe dis-
ease. In comparison, 72% of participants with watery diarrhea
but no cholera diagnosis had mild disease, and the remaining
28% had moderate disease; none met criteria for severe disease.
Bivariable analysis of reported cholera. A higher propor-
tion of participants in the oldest quartile (> 43 years old)
reported a cholera diagnosis (23%) than participants in youn-
ger age quartiles (16–17%) (Table 3). A cholera diagnosis
Figure 2. A, Self-reported dates of watery diarrhea onset for participants reporting a cholera diagnosis, cholera serosurvey, Grande Saline,
Haiti, 2010–2011 (n = 354). B, Grande Saline cholera cases reported to Ministry of Health and Population (MSPP) surveillance, Haiti, 2010–2011.
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was reported in similar proportions by females and males
(OR = 1.05, 95% CI = 0.85–1.29). A cholera diagnosis was
more commonly reported by participants who were illiterate
(OR = 1.73, 95% CI = 1.40–2.14), did not speak French (OR =
1.86, 95% CI = 1.23–2.81), and who reported using antacids
(OR = 1.73, 95% CI = 1.32–2.27). A cholera diagnosis was
also more commonly reported by participants in households
lacking a cell phone (OR = 1.35, 95% CI = 1.07–1.69), radio
(OR = 1.39, 95% CI = 1.09–1.78), and electricity (OR = 2.22,
95% CI = 1.07–4.64). Equal proportions of participants with
blood group O and those with other blood groups reported a
cholera diagnosis (23%).
Serum antibody testing. Based on validation results, a titer
of 320 was set as the threshold for seropositivity for the Ogawa
and Inaba vibriocidal assays. Secondary analyses examined
survey results using lower, more lenient, vibriocidal titers of
80 and 160. Specific OD threshold values were calculated for
both anti-CT ELISAs. Among the 2,527 (96%) participants
from whom we collected serum, 980 (39%) had a positive
Ogawa or Inaba vibriocidal result (titer ³ 320) (Table 4),
1,331 (53%) participants had a vibriocidal titer ³ 160, and
1,626 (64%) had a titer ³ 80; 732 (29%) participants had a
positive anti-CT test result for IgA or IgG. None of the 50 pre-
epidemic serum specimens had a vibriocidal Ogawa titer > 80;
two had a vibriocidal Inaba titer of 320.
Bivariable analysis of seropositivity. Participants 13–23
years old had the highest prevalence of vibriocidal seroposi-
tivity (46%), and adults > 43 years old had the lowest (30%)
(Table 5). Whereas a cholera diagnosis was most commonly
reported by participants in the oldest age quartile, vibriocidal
seropositivity was less common among participants in this
quartile compared with the youngest quartile (OR = 0.59,
95% CI = 0.47–0.74). The prevalence of seropositivity in each
age quartile varied according to the antibody test (Figure 3).
Adults in the oldest age quartile (> 43 years old) had the
highest seroprevalence of anti-CT IgA (17%), whereas chil-
dren in the youngest age quartile (2–12 years old) had the
highest seroprevalence of anti-CT IgG (35%). The prevalence
of vibriocidal seropositivity did not differ by sex before or
after adjustment for age. No association was seen between
length of time from diarrhea to serum collection and antibody
titer for any of the four assays (data not shown). Participants
with blood group O were not significantly more likely to be
seropositive than those with other blood groups (OR = 0.92,
95% CI = 0.69–1.22).
Spectrum of illness. Among all participants, regardless of
antibody status, 6.2% had severe disease, 9.1% had moderate
disease, 6.0% had mild disease and 78.7% were asymptom-
atic (Table 6). Among the 948 participants with vibriocidal
titers ³ 320 and severity data, 9.0% had severe disease, 9.7%
had moderate disease, 6.9% had mild disease, and 74.5% were
asymptomatic. A higher proportion of the 717 participants
with positive anti-CT results had severe disease (12.3%) than
did the vibriocidal group (9.0%), and a smaller proportion
were asymptomatic (68.9% versus 74.5%).
Risk factors for severe cholera.Among 77 seropositive par-
ticipants with blood grouping results who reported watery
diarrhea, those with blood group O were not significantly
more likely than those with other blood groups to report
overnight hospitalization (OR = 2.11, 95% CI = 0.81–5.49) or
receipt of IV fluids (OR = 1.91, 95% CI = 0.75–4.84). Among
Table 3
Comparisons of demographic and clinical characteristics with reported
cholera diagnosis, cholera serosurvey, Grande Saline, Haiti, March
22–April 6, 2011 (n = 2,543)*
Characteristic
No. reporting
cholera diagnosis % OR† 95% CI
Total 466 18
Age quartile, years
2–12 114 16 Ref
13–23 97 17 1.06 0.79–1.43
24–43 107 16 1.02 0.76–1.37
44–90 148 23 1.63 1.23–2.17‡
Sex
Female 279 19 1.05 0.85–1.29
Male 187 18 Ref
Literacy
Illiterate 269 23 1.73 1.40–2.14‡
Literate 195 14 Ref
Speaks French
No 434 19 1.86 1.23–2.81‡
Yes 32 11 Ref
Reported HIV diagnosis
No 442 18 1.01 0.22–4.64
Yes 2 18 Ref
Reported pregnant, among females 10–55 years (n = 1,040)
Pregnant 20 26 1.63 0.96–2.78
Not pregnant 165 18 Ref
Reported antacid use
User 103 26 1.73 1.32–2.27‡
Non-user 362 17 Ref
Cell phone in household
No 261 21 1.35 1.07–1.69‡
Yes 205 16 Ref
Radio in household
No 328 20 1.39 1.09–1.78‡
Yes 138 15 Ref
Electricity in household
No 457 19 2.22 1.07–4.64‡
Yes 9 9 Ref
Primary water source from river or canal
No 298 18 0.98 0.77–1.24
Yes 165 18 Ref
Treated drinking water
No 85 14 0.78 0.58–1.04
Yes 378 19 Ref
Blood group testing (n = 837)
O 85 23 0.97 0.70–1.36
A, B, or AB 107 23 Ref
*OR = odds ratio; CI = confidence interval; Ref = referent; HIV = human immuno-
deficiency virus.
†Estimated population OR and 95% CI calculated by bivariable logistic regression,
adjusting for household design effect.
‡Statistically significant at alpha = 0.05.
Table 4
Serum testing for Vibrio cholerae antibodies and blood group
among 2,527 cholera serosurvey participants, Grande Saline, Haiti,




Vibriocidal* ³ 320 980 39
Vibriocidal Ogawa ³ 320 711 28
Vibriocidal Inaba ³ 320 589 23
Vibriocidal* ³ 160 1,331 53
Vibriocidal* ³ 80 1,626 64
Cholera toxin (IgA or IgG) 732 29
Cholera toxin IgA 279 11
Cholera toxin IgG 573 23
Vibriocidal* ³ 320 or CT (IgA or IgG) 1,303 52
*Either vibriocidal Ogawa or Inaba assay.
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seropositive participants, antacid use was significantly associ-
ated with increased disease severity (Table 7). After adjusting
for age and antacid use, lack of a cell phone (adjusted OR
[aOR] = 1.46, 95% CI = 1.06– 2.01), radio (aOR = 1.63, 95%
CI = 1.15–2.32), or electricity (aOR = 2.96, 95%CI = 1.04–8.45)
in the household were associated with increased disease
severity among seropositive participants. Illiteracy, inability
to speak French, primarily using water from the river or canal,
and treating drinking water were not significantly associated
with increased disease severity after adjusting for age and
antacid use among the subset of seropositive participants.
Deaths within the households.Among a subset of 589 house-
holds with information about all household members (including
participants and non-participants), there were 2,396 residents,
of whom 311 were reported to have had cholera (including
participants). Within these households, there were 13 cholera
deaths reported by study participants; estimated case-fatality
rate = 4%. Based on these limited data, approximately 1 in
185 household residents died of cholera.
DISCUSSION
Grand Saline Commune in Haiti experienced a large num-
ber of cholera cases from the very beginning of the cholera
epidemic in October 2010 and had a reported cumulative
attack rate of 18% within five months (MSPP Surveillance,
unpublished data). During March 22–April 6, 2011, we con-
ducted a large seroepidemiologic survey in the commune, and
found that 39% of study participants had vibriocidal titers
³ 320 and nearly two-thirds had vibriocidal titers ³ 80, sug-
gesting that V. cholerae infection was widespread. Of those
with vibriocidal titers ³ 320, 9% met the criteria for severe
cholera and an additional 17% had moderate or mild diar-
rhea. Although the strain responsible for the outbreak was
biotype El Tor, this proportion of severe disease is substan-
tially higher than previous estimates (2%) for typicalV. cholerae
biotype El Tor and is closer to estimates for classical biotype
infections (severe disease in 11%).5,7 However, previous esti-
mates were derived primarily from areas with endemic cholera,
and the heightened severity observed in this study is likely
explained, at least in part, by participants’ lack of pre-existing
immunity to toxigenic V. cholerae.
High rates of severe disease from El Tor V. cholerae infec-
tion during epidemics among cholera-naive populations have
Table 5
Comparisons of demographic and clinical characteristics with Vibrio
cholerae seropositivity, cholera serosurvey, Grande Saline, Haiti,
March 22–April 6, 2011 (n = 2,527)*
Characteristic
No.
seropositive† % OR‡ 95% CI
Total 980 39
Age quartile, years
2–12 282 42 Ref
13–23 268 46 1.20 0.96–1.50
24–43 242 37 0.82 0.66–1.02
44–90 187 30 0.59 0.47–0.74§
Sex
Female 601 40 1.14 0.97–1.34
Male 379 37 Ref
Literacy
Literate 562 42 1.29 1.10–1.52§
Illiterate 416 36 Ref
Speaks French
No 868 39 1.01 0.78–1.30
Yes 112 38 Ref
Reported HIV diagnosis
No 937 39 1.27 0.32–5.12
Yes 3 33 Ref
Reported pregnant among women 10–55 years old (n = 1,017)
Pregnant 33 46 1.27 0.78–2.06
Not pregnant 378 40 Ref
Reported antacid use
User 142 35 0.83 0.67–1.03
Non-user 836 39 Ref
Primary water source from river or canal
No 629 39 1.01 0.84–1.21
Yes 337 39 Ref
Treated drinking water
No 216 38 0.96 0.78–1.18
Yes 748 39 Ref
Watery diarrhea since October 2010¶
Yes 243 47 1.54 1.26–1.87§
No 706 37 Ref
Cholera diagnosis since October 2010¶
Yes 215 48 1.59 1.28–1.96§
No 736 37 Ref
Clinical (among those with watery diarrhea, n = 517)
Vomited more than once
Yes 114 51 1.33 0.94–1.90
No 128 44 Ref
Leg cramps
Yes 166 45 0.71 0.48–1.05
No 76 53 Ref
Rice water stool
Yes 211 49 1.89 1.14–3.12§
No 26 34 Ref
Bloody stool
Yes 25 46 1.01 0.60–1.70
No 179 46 Ref
Used ORS at home
Yes 208 48 1.29 0.82–2.04
No 35 42 Ref
Took antibiotic
Yes 160 46 0.86 0.61–1.22
No 81 49 Ref
Went to HF
Yes 177 48 1.14 0.79–1.65
No 65 45 Ref
Treatment (among those who visited HF, n = 370)
Received ORS at HF
Yes 160 49 1.66 0.88–3.16
No 17 37 Ref
Received IV fluids at HF
Yes 110 53 1.59 1.06–2.40§






seropositive† % OR‡ 95% CI
Hospitalized overnight
Yes 100 53 1.55 1.02–2.36§
No 77 42 Ref
IV fluids and hospitalization
Yes 85 57 1.82 1.20–2.76§
No 92 42 Ref
Blood group testing (n = 866)
O 137 35 0.92 0.69–1.22
A, B, or AB 180 38 Ref
*OR = odds ratio; CI = confidence interval; Ref = referent; HIV = human immuno-
deficiency virus; ORS = oral rehydration salts; HF = health facility; IV = intravenous.
†Defined by vibriocidal Ogawa or vibriocidal Inaba titer ³ 320.
‡Estimated population OR and 95% CI were calculated by bivariable logistic regression,
adjusting for household design effect.
§Statistically significant at alpha = 0.05.
¶Excludes 79 participants who reported cholera but not watery diarrhea.
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been observed. During a 1994 outbreak of El Tor cholera
among Rwandan refugees in the former Zaire, an estimated
6–10% of refugees died within the first month; most deaths
were attributed to diarrheal illness.30 The rate of severe chol-
era in that population was likely high, although other factors,
including a concomitant shigellosis outbreak, a high rate of
acute malnutrition, and a severe drinking water shortage,
likely contributed.30,31
In addition to immunologic status, several factors may have
contributed to the increased severity seen in our study com-
pared with previous El Tor estimates, including the introduc-
tion of an El Tor strain that produces a CT similar to that of
the classical biotype. The explosiveness of the epidemic2,25
is also compatible with exposure to a high inoculum of
V. cholerae with a temporary increase in its infectivity because
of rapid passage of the organism through many hosts.32 The
high seroprevalence in our study, and the relatively high pro-
portion of persons with severe disease, suggests that exposure
was widespread and potentially at high levels. Future cholera
response efforts should consider the high degree of severity
observed when projecting resource needs.
Individual risk factors also influence the spectrum of illness
from V. cholerae infection. Blood group O is not a likely
explanation for the high observed proportion of severe dis-
ease. Group O, compared with other ABO blood groups, was
not a risk factor for hospitalization in this study. Furthermore,
prevalence of blood group O in our sample (45%) is not
substantially greater than that in cholera-endemic areas such
as Bangladesh13 and is substantially lower than that in many
Latin American countries affected by cholera in the early
1990s (> 90%).14,16
Low gastric acidity and antacid use are previously identi-
fied risk factors for symptomatic cholera.33 Although we did
not measure gastric acidity directly, 16% of participants
Figure 3. Proportion of participants within each age group seropositive for Vibrio cholerae antibody tests, cholera serosurvey, Grande Saline,
Haiti, 2011. Anti-CT: antibody against cholera toxin.
Table 6
Severity spectrum of diarrheal disease among 2,447 participants with positive results for Vibrio cholerae antibody testing, cholera serosurvey,
Grand Saline, Haiti, March 22–April 6, 2011*
Antibody result Total
Asymptomatic Mild† Moderate‡ Severe§
No. % 95% CI No. % 95% CI No. % 95% CI No. % 95% CI
Vibriocidal¶ ³320 948 706 74.5 71.4–77.6 65 6.9 5.0–8.6 92 9.7 7.8–11.6 85 9.0 7.1–10.8
Vibriocidal¶ ³160 1,293 977 75.6 73.0–78.1 83 6.4 5.0–7.9 120 9.3 7.6–10.9 113 8.7 7.2–10.3
Vibriocidal¶ ³80 1,581 1,205 76.2 73.9–78.6 101 6.4 5.0–7.7 149 9.4 7.9–10.9 126 8.0 6.6–9.3
Anti-CT positive 717 494 68.9 65.3–72.5 52 7.3 5.3–9.2 83 11.6 9.2–14.0 88 12.3 9.8–14.7
Vibriocidal¶ ³ 320 or anti-CT positive 1,265 935 73.9 71.2–76.6 88 7.0 5.4–8.5 129 10.2 8.5–11.9 113 8.9 7.3–10.6
Vibriocidal¶ < 320 and anti-CT negative 1,182 996 84.3 82.1–86.4 58 4.9 3.6–6.2 91 7.7 6.2–9.2 37 3.1 2.1–4.1
All participants
(n = 2,538) 2,538 1,998 78.7 76.9–80.6 153 6.0 4.9–7.1 230 9.1 7.9–10.3 157 6.2 5.2–7.2
*CI = confidence interval; CT = cholera toxin.
†Defined as watery diarrhea without a visit to a health facility.
‡Defined as watery diarrhea with a health facility visit, but not meeting criteria for severe disease.
§Defined as watery diarrhea with receipt ofintravenous fluids and overnight hospitalization.
¶Either vibriocidal Ogawa or Inaba assay.
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reported using antacids since the start of the cholera epi-
demic, and seropositive participants who used antacids were
more likely to have met the criteria for severe disease than
seropositive participants who did not report antacid use.
No data were collected on the frequency or duration of ant-
acid use, and the possibility exists that some participants took
antacids after developing cholera rather than before, but the
strength of the association suggests that further study of ant-
acid use during cholera outbreaks is warranted and that
unnecessary antacid use should be discouraged.
Three markers of higher socioeconomic status (mobile
phone, radio, and electricity in the household), were associ-
ated with milder illness severity among seropositive par-
ticipants, although other measures (literacy and speaking
French) were not. A difference in severity among socio-
economic groups could have been caused by differences in
V. cholerae dosage as a result of better household hygiene or
better access to safe water and sanitation. No differences in
illness severity were observed by primary source of drinking
water or use of water treatment. However, based on observa-
tions within the commune, alternate water sources were likely
common and water treatment was intermittent based on avail-
ability of treatment supplies. Nutritional differences might
also have contributed to the difference between socioeconomic
groups. Micronutrient retinol, zinc, and iron deficiencies,
likely more common among people of lower socioeconomic
status, have been associated with more severe illness,12,19,34
whereas studies conflict on whether chronic macronutrient
deficiency influences diarrhea severity among those infected
with V. cholerae.35,36
Cholera was not observed in Haiti before 2010,2 and paired
serum specimens were not available. Therefore, we measured
threshold cutoffs for single serum specimens. Serologic testing
has limitations and interpretations of results must be carefully
considered. Because the study was conducted several months
after the start of the outbreak, it is likely that some partici-
pants’ antibody titers waned before serum collection. Consid-
ering that test validations must be conducted with serum from
confirmed cases, we explored the outcome of seropositivity
rates at lower, less specific cutoff titers of 80 and 160. The
distribution of illness severity was similar among participants
with vibriocidal titers ³ 320, ³ 160, ³ 80, and among those with
a positive anti-CT test result or a vibriocidal titer ³ 320,
suggesting that these illness severity estimates were robust
across a range of antibody titers.
Detailed clinical records were not available to assess illness
severity and we thus relied on self-report, which is subject
to recall bias. However, two lines of evidence suggest that
self-report was a reliable indicator of illness and treatment
intensity. First, the epidemic curve created from participant
reports of diarrhea onset (Figure 2A) is similar to reported
national cholera surveillance data from Grande Saline Com-
mune at the time of the survey (Figure 2B). Second, the pro-
portion of participants reporting a cholera diagnosis (18%)
was the same as the cumulative cholera incidence (18%) from
national surveillance data for Grande Saline (MSPP Surveil-
lance, unpublished data). Similar to previous studies, we used
level of treatment received to classify disease severity.5,6
Although number of stools in 24 hours might be difficult to
recall, participants and their families would likely remember a
health facility visit, overnight stay, or IV fluid administration
during the midst of an epidemic.
The study’s sampling method was not completely random
and a response rate could not be calculated, which might limit
the generalizability of this study to the entire commune. How-
ever, several factors mitigate this problem. More than 10% of
the commune was sampled and sampling was well-distributed
among the commune’s 13 villages. Also, the community was
generally willing to participate, which was helped by involve-
ment of local community health workers and the health
Table 7
Unadjusted and adjusted odds ratios for increased diarrheal illness severity among seropositive and seronegative participants, cholera serosurvey,
Grande Saline, Haiti, March 22–April 6, 2011*
Variable
Seropositive† (n = 1,303) Seronegative (n = 1,224)
Unadjusted OR (95% CI) Adjusted OR‡ (95% CI) Unadjusted OR (95% CI) Adjusted OR‡ (95% CI)
Age quartile, years
2–12 Ref Ref Ref Ref
13–23 0.86 (0.57– 1.28) 0.82 (0.55–1.23) 1.54 (1.00–2.38)§ 1.47 (0.95–2.26)
24–43 0.74 (0.49– 1.11) 0.64 (0.42–0.97)§ 2.11 (1.41–3.16)§ 1.82 (1.20–2.77)§
44–90 1.36 (0.91– 2.04) 1.13 (0.75–1.71) 2.74 (1.84–4.07)§ 2.34 (1.55–3.54)§
Antacid use, stratified by age quartile 1.93 (1.30– 2.85)§ 1.99 (1.46–2.71)§
2–12 13.36 (4.28–41.74)§ 11.12 (3.77–32.80)§
13–23 2.53 (1.21–5.29)§ 2.10 (1.02–4.36)§
24–43 1.92 (1.13–3.27)§ 1.60 (1.01–2.53)§
44–90 1.49 (0.89–2.51) 1.24 (0.81–1.89)
No cell phone in household 1.51 (1.10– 2.08)§ 1.46 (1.06–2.01)§ 1.14 (0.87–1.49) 1.13 (0.86–1.49)
No radio in household 1.60 (1.13–2.27)§ 1.63 (1.15–2.32)§ 1.24 (0.93–1.66) 1.28 (0.95–1.71)
No electricity in household 2.78 (0.99–7.85) 2.96 (1.04–8.45)§ 1.43 (0.67–3.08) 1.48 (0.68–3.21)
Illiterate 1.28 (0.95–1.73) 1.18 (0.85–1.63) 1.97 (1.49–2.60)§ 1.93 (1.40–2.64)§
Unable to speak French 1.11 (0.68–1.82) 1.06 (0.65–1.75) 1.96 (1.17–3.30)§ 2.26 (1.34–3.83)§
Primary water source from river or canal 1.16 (0.83–1.61) 1.22 (0.87–1.70) 0.82 (0.61–1.11) 0.82 (0.61– 1.11)
Treated drinking water 1.13 (0.77–1.64) 1.18 (0.80–1.72) 1.16 (0.83–1.62) 1.18 (0.84–1.65)
Blood group O vs. other blood groups (n = 835) 1.12 (0.66– 1.90) 1.30 (0.75–2.23) 0.90 (0.61–1.34) 0.96 (0.65–1.43)
*Illness severity was coded on 0–3 ordinal scale (no diarrhea, diarrhea without a visit to a health facility [mild], diarrhea with a visit to health facility but not receiving intravenous fluids and
overnight hospitalization [moderate], and diarrhea with receipt of intravenous fluids and overnight hospitalization [severe]). OR = odds ratio; CI = confidence interval; Ref = referent.
†Defined by vibriocidal Ogawa or Inaba titer ³ 320
‡Adjusted OR was calculated by proportional-odds cumulative logistic regression adjusted for age quartile (for antacid use), antacid use (for age quartile) or age quartile and antacid use
(other variables).
§Statistically significant at alpha = 0.05.
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center. Although adult men were undersampled, no differ-
ences were seen between the sexes for cholera diagnoses
or seropositivity either before or after adjustment for age.
Importantly, proportions of severe, moderate, and mild illness
were calculated among seropositive participants, rather than
among the entire sample, and are thus less susceptible to
selection bias.
In summary, severe cholera developed in 9% of seropos-
itive participants, moderate or mild diarrhea developed in
17%, and approximately 75% were asymptomatic. Nearly
half of participants (45%) had positive vibriocidal or anti-CT
IgA test results, both of which are associated with protective
immunity.21,24 According to national surveillance data, in the
two years since the study, the cumulative cholera attack rate
increased from 18% to 24%, a relatively small increase com-
pared with the rate of infection in the commune during the first
five months of the epidemic (MSPP Surveillance, unpublished
data). These findings suggest that a large proportion of
Grande Saline commune residents developed protective immu-
nity within several months of the beginning of the epidemic.
The commune’s high attack rate in the first few months of the
epidemic also highlights the critical lack of access to safe
water and hygiene, particularly residents’ reliance on the river
and canals for drinking water.
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